CD8A and COVID-19: The HLA-A*24:02 restricted M198-206 is currently reported the most immunodominant membrane-derived SARS-CoV-2 epitope, and A24/M198-specific CD8+ T cell responses can effectively suppress propagation of variants of concern including omicron strain and associate with COVID-19 clinical severity (38), and thus it appears to be a potential favorable target for next-generation vaccines or adoptive immunotherapy.